Electronic cigarette (ECIG) nicotine delivery and other effects may depend on liquid nicotine concentration and user experience. This study is the first to systematically examine the influence of ECIG liquid nicotine concentration and user experience on nicotine delivery, heart rate, puff topography, and subjective effects. Thirty-three ECIG-experienced individuals and 31 ECIG-naïve cigarette smokers completed 4 laboratory conditions consisting of 2, 10-puff bouts (30-sec interpuff interval) with a 3.3-V ECIG battery attached to a 1.5-⍀ "cartomizer" (7.3 W) filled with 1 ml ECIG liquid. Conditions differed by liquid nicotine concentration: 0, 8, 18, or 36 mg/ml. Participants' plasma nicotine concentration was directly related to liquid nicotine concentration and dependent on user experience, with significantly higher mean plasma nicotine increases observed in ECIG-experienced individuals relative to ECIG-naïve smokers in each active nicotine condition. When using 36 mg/ml, mean plasma nicotine increase for ECIG-experienced individuals was 17.9 ng/ml (SD ϭ 17.2) and 6.9 (SD ϭ 7.1; p Ͻ .05) for ECIG-naïve individuals. Between-group differences were likely due to longer puffs taken by experienced ECIG users: collapsed across condition, mean puff duration was 5.6 sec (SD ϭ 3.0) for ECIG-experienced and 2.9 (SD ϭ 1.5) for ECIG-naïve individuals. ECIG use also suppressed nicotine/tobacco abstinence symptoms in both groups; the magnitude of abstinence symptom suppression depended on liquid nicotine concentration and user experience. These and other recent results suggest that policies intended to limit ECIG nicotine delivery will need to account for factors in addition to liquid nicotine concentration (e.g., device power and user behavior).
Electronic cigarettes (ECIGs) are a class of products that use an electrically powered heating element to aerosolize a liquid, which often contains nicotine, for user inhalation Grana, Benowitz, & Glantz, 2014; Hajek, 2014) . The prevalence of ECIG use has been globally increasing (Adkison et al., 2013; Singh et al., 2016) , but ECIG effects (e.g., nicotine delivery, user subjective experience, health outcomes) remain unclear. This lack of clarity may be due, in part, to the variability of design features and liquid constituents across this class of products. In August 2016, the U.S. Food and Drug Administration began regulating ECIGs and their "parts and components" ("Deeming tobacco products", 2016) ; the European Union also regulates ECIG liquids (i.e., they cannot exceed 20 mg/ml; European Union Directive, 2014/ 40/EU). Systematic investigations regarding how characteristics of ECIG devices, liquids, and user puffing behaviors influence ECIG effects, including nicotine delivery, may be valuable in informing future evidence-based policy decisions regarding ECIGs.
ECIGs vary markedly, but they typically consist of an electric power source (e.g., battery), a heating element (called an atomizer), and a reservoir that stores a liquid solution. The liquid generally contains solvents such as propylene glycol (PG) and/or vegetable glycerin (VG), flavorants, and nicotine in concentrations that range from 0 to 36 mg/ml or higher . It is important to note that varying device features (e.g., power), liquid nicotine concentration, and puff duration can alter the amount of nicotine emitted from the device (Talih et al., 2015) . Similarly, the ability of an ECIG to deliver nicotine to the user may be influenced by each of these factors. For example, regarding device power, a nonsystematic evaluation of nicotine delivery in a small sample of experienced ECIG users who provided their own device and liquid demonstrated that ECIGs with mean power of 71.6 W delivered significantly more nicotine than ECIGs with mean power of 8.6 W despite the lower power devices being paired with a higher nicotine concentration liquid (Wagener et al., 2017) . In addition, higher liquid nicotine concentration increases user blood nicotine concentration (Dawkins, Kimber, Doig, Feyerabend, & Corcoran, 2016 ; also see Lopez, Hiler, Soule, et al., 2016; Ramôa et al., 2016) . Furthermore, experienced ECIG users obtain more nicotine than ECIG-naïve cigarette smokers (Farsalinos et al., 2015) , likely reflecting differences in puff topography: experienced ECIG users take longer puffs relative to ECIG-naïve cigarette smokers (e.g., Farsalinos et al., 2015; Hua, Yip, & Talbot, 2013; Spindle et al., 2017) . Thus, understanding the nicotine delivery of ECIGs as a product class will require some method of accounting for the three factors known to influence nicotine delivery: device features, liquid constituents, and user behavior (e.g., .
Because nicotine is psychoactive, its delivery to blood likely influences ECIG-induced subjective effects. In previous clinical laboratory studies, approximately 12-h nicotine-abstinent ECIG-naïve cigarette smokers reported at least partial suppression of tobacco abstinence symptoms after ECIG use (Dawkins, Turner, Hasna, & Soar, 2012; Nides, Leischow, Bhatter, & Simmons, 2014; Vansickel, Cobb, Weaver, & Eissenberg, 2010) ; approximately 12-h nicotine-abstinent, experienced ECIG users reported similar effects (Dawkins & Corcoran, 2014; Spindle et al., 2017; Vansickel & Eissenberg, 2013) . Evaluating tobacco abstinence symptom suppression, as well as other subjective effects, in current tobacco cigarette smokers is important because the ability of these products to suppress tobacco abstinence may underlie their potential capacity to serve as cigarette substitutes in this population (e.g., Etter, 2013; Hajek, 2014) . Characterizing these subjective effects in ECIG users who are not current tobacco smokers is also important because any such effects may reveal the extent to which ECIGs support nicotine dependence in that population (e.g., Eissenberg, 2004) . Thus, in addition to understanding the nicotine delivery potential of this product class, regulators may also benefit from further understanding of the factors that influence ECIG subjective effects.
The present study expands on preliminary reports that examined the influence of liquid nicotine concentration on plasma nicotine concentration (Lopez, Hiler, Soule, et al., 2016; Ramôa et al., 2016) by increasing sample size, comparing across experienced ECIG users and ECIG-naïve cigarette smokers, and reporting on heart rate (HR) and subjective effects. Notably, unlike prior evaluations of ECIGs, the present study seeks to evaluate these products systematically by holding constant several important device features (e.g., battery power, heater resistance) and liquid constituents (e.g., PG:VG ratio) while manipulating liquid nicotine concentration and user experience. We hypothesized that liquid nicotine concentration and user experience would directly influence outcomes such as plasma nicotine delivery, HR, puff topography, and user subjective effects. teers were recruited by advertisement and word of mouth. Of the 127 individuals who provided informed consent for this study, data from 63 were not included-41 because they were ineligible at screening and thus never participated in any sessions and 22 because their participation was discontinued (10 failed to attend scheduled sessions, 6 lacked venous access, 3 were noncompliant with presession abstinence criteria, 1 experienced an adverse event [nausea], 1 exhibited elevated blood pressure, and 1 exhibited elevated HR). Of those 64 participants whose data were included in the analysis, 33 were ECIG-experienced individuals and 31 were ECIG-naïve cigarette smokers.
Individuals were eligible to participate if they reported being healthy and 18 -55 years of age. ECIG-experienced individuals were eligible if they reported using their ECIG for Ն3 months, using Ն1 ml of ECIG solution daily, using an ECIG liquid with a nicotine concentration Ն8 mg/ml, and currently using Յ5 conventional tobacco cigarettes daily as well as if they provided an expired air carbon monoxide (CO) sample with a concentration of Յ10 ppm at screening (BreathCO monitor; Vitalograph, Lenexa, KS). The criterion of Ն8 mg/ml liquid nicotine concentration was intended to ensure that ECIG users were experienced with nicotine-containing liquids before their participation in this study. ECIG-naïve cigarette smokers were eligible if they reported using Ն10 conventional tobacco cigarettes daily, Ͻ5 ECIG uses in their lifetime, and if they provided an expired CO sample with a concentration Ն15 ppm at screening as an indicator of current smoking status. Individuals were excluded if they reported history of chronic disease or psychiatric condition, regular use of a prescription medication (aside from birth control), marijuana use Ͼ10 days and alcohol use Ͼ25 days in the past 30 days, and any illicit drug use (e.g., cocaine, opioids, benzodiazepines, and methamphetamine) in the past 30 days. For women, a positive pregnancy test (by urinalysis) at screening was exclusionary.
During screening, demographic information was collected and two dependence measures were administered. The Fagerström Test for Nicotine Dependence (FTND) was modified such that the word e-cigarette appeared for ECIG-experienced individuals (Heatherton, Kozlowski, Frecker, & Fagerström, 1991) . For the Penn State Dependence Index, the Electronic Cigarette Dependence Index was administered to ECIG-experienced individuals and the Cigarette Dependence Index was administered to ECIG-naïve cigarette smokers (Foulds et al., 2015) .
Materials
During each session, participants used an "eGo" 3.3-V, 1,000-mAh battery with a 1.5-⍀, dual-coil, 510-style "cartomizer" (7.3 W; cartomizer produced by SmokTech, Shenzhen, China). These device components were selected after preliminary testing revealed that their nicotine emissions approached those of a tobacco cigarette under some conditions (see Talih et al., 2015 Talih et al., , 2017 . The cartomizer was preloaded with 1 ml of a flavored liquid (tobacco or menthol; chosen by participants at screening) that was composed of 70% PG and 30% VG (AVAIL Vapor, Richmond, VA). Liquid nicotine concentration differed by session (0, 8, 18 , or 36 mg/ml) and was verified before administration; on average, actual nicotine content was Ϯ2 mg of labeled nicotine content.
Using an ECIG topography instrument developed at the American University of Beirut (see Spindle, Breland, Karaoghlanian, Shihadeh, & Eissenberg, 2015) , puff topography was measured throughout each ECIG-use bout. The device uses a mouthpiece, pressure transducer, and calibrated software to detect flow-induced pressure changes that were amplified, digitized, and sampled every 100 msec. The pressure transducer and the orifice dimensions of each mouthpiece allowed measurement at puff velocities as low as 3 ml/sec. This instrument does not interfere with the nicotine delivery or subjective effects observed after ECIG use (see Spindle et al., 2017) .
Procedures
Participants completed four double-blind, approximately 2.5-h sessions at VCU's Clinical Behavioral Pharmacology Laboratory. Session order was randomized and sessions were separated by a minimum of 48 h. Before each session, participants were instructed to abstain from nicotine/tobacco and/or ECIG use for Ն12 h. Abstinence from combustible tobacco was verified via participants' expired air CO (Յ10 ppm), and abstinence from ECIGs was verified retrospectively using a criterion of plasma nicotine concentration Յ5 ng/ml (as in Spindle et al., 2017 ; see Data Preparation and Analysis section). In each session, participants completed two 10-puff ECIG-use bouts (with 30-sec interpuff interval [IPI] ) separated by 60 min (as in Lopez, Hiler, Maloney, Eissenberg, & Breland, 2016; Vansickel et al., 2010) . A venous catheter was used to sample 7 ml of blood 10 times per session (5 min before and 5, 15, 30, 45, and 55 min after the onset of bout 1 and 5, 15, 30, and 45 min after the onset of bout 2). Subjective questionnaires were administered immediately after each blood sample. Physiological recording of HR occurred throughout each session, and blood pressure was monitored regularly for safety but was not included as an outcome measure.
Outcome Measures
Plasma nicotine and HR. All blood samples were centrifuged, stored at Ϫ70°C, and analyzed for nicotine concentration with a limit of quantitation (LOQ) of 2 ng/ml (see Breland, Kleykamp, & Eissenberg, 2006 ) by VCU's Bioanalytical Analysis Core Laboratories. HR was monitored every 20 sec (Criticare Systems Model 507, Waukesha, WI).
Puff topography. During each of the two 10-puff ECIG-use bouts, puff topography measures included puff number, puff duration (measured in seconds), puff volume (measured in milliliters) flow rate (i.e., puff velocity measured in milliliters per second), and IPI (measured in seconds and defined as the time between the onset of one puff and the onset of a subsequent puff as in Spindle et al., 2017; Vansickel et al., 2010) . Although puff number and IPI were recorded, they were held constant to 10 puffs and 30-sec IPI.
Subjective questionnaires. Five questionnaires were administered at 10 separate time points, 4 of which were administered using a computerized Visual Analog Scale (VAS) that consisted of a word or phrase centered on a horizontal line with "not at all" on the left and "extremely" on the right. To record responses, participants clicked a mouse at any point on a horizontal line and scores were expressed as a percentage of total line length (0 -100). The VAS Questionnaires included the modified Hughes-Hatsukami Withdrawal Scale (11 items, omitting 2 items from the original: "Increased eating" and "Insomnia/Disturbed sleep"; Hughes & This document is copyrighted by the American Psychological Association or one of its allied publishers.
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Hatsukami, 1986), the Direct Effects of Nicotine Scale (10 items; Evans, Blank, Sams, Weaver, & Eissenberg, 2006) , the Direct Effects of ECIG-use Scale (10 items; Foulds et al., 1992; Pickworth, Bunker, & Henningfield, 1994) , and an acceptability questionnaire used to assess the extent to which the topography mouthpiece interfered with normal ECIG-use behavior (6 items; Blank, Disharoon, & Eissenberg, 2009; Spindle et al., 2015) . The fifth questionnaire was the 10-item Tiffany-Drobes Questionnaire of Smoking Urges (QSU) Brief. Scores from the questionnaire's individual items form two factors: intention to smoke (0 -30) and anticipation of relief from withdrawal symptoms (0 -24; Cox, Tiffany, & Christen, 2001) . Items on the Hughes-Hatsukami Withdrawal Scale and Tiffany-Drobes QSU Brief were modified for ECIG-experienced individuals such that whenever the word cigarette appeared in the original, the word e-cigarette appeared instead.
Data Preparation and Analysis
As in other studies (Lopez, Hiler, Soule, et al., 2016; Vansickel et al., 2010) , plasma nicotine values below the LOQ were replaced with the LOQ (2 ng/ml) because this approach is more conservative than assuming that values below the LOQ were zero. HR data were averaged for the 5 min before each blood sampling and the 5 min during each ECIG-use bout. For topography data, two data cleaning procedures were performed automatically in real time by the device's software to correct for transducer noise before analysis: any two puffs that were separated by 300 msec or less were combined into one puff and any puffs with duration less than 300 msec were deleted; no record of these automatic corrections was maintained. The remaining data for each topography variable were averaged for each participant within each bout, resulting in two values for each topography measure for each participant.
Mixed analyses of variance (ANOVAs) with group as the between-subject factor (two levels; ECIG experienced or naïve) and liquid nicotine concentration (hereafter referred to as "condition"; four levels) and time as the within-subject factors were conducted for plasma nicotine (10 levels of time), HR (10 levels of time), and topography (2 levels of time). Subjective effect data also had 10 levels of time except for the Direct Effects of ECIGuse and Topography Acceptability Questionnaires that had 9 levels; the baseline time point was omitted from analysis because participants had not sampled the product or used the topography equipment at baseline. Separate ANOVAs were conducted to examine each individual item from all subjective questionnaires. Huynh-Feldt corrections were used to adjust for potential violations of the sphericity assumption.
For all outcome measures, to test differences across conditions within a group (e.g., to test the effects of nicotine concentration for ECIG-experienced individuals), post hoc comparisons were made using Tukey's honestly significant difference (HSD) test to control for overall Type I error rate (Tukey, 1949) . To test differences within conditions and between groups (i.e., ECIG-experienced vs.
-naïve individuals), planned contrasts (i.e., independent t tests) were used to make comparisons only for the time points immediately after each ECIG-use bout. Because these planned contrasts were orthogonal at each time point, no corrections were made to Type I error rate (Keppel, Saufley, & Tokunaga, 1992) .
Before conducting the main study analyses for plasma nicotine, HR, topography, and subjective effects previously described, plasma nicotine data were first inspected to determine if any participants were not abstinent from nicotine/tobacco for the required Ն12 h before the onset of any session. A criterion level of Ͻ5 ng/ml was used for this determination (i.e., individuals with baseline plasma nicotine concentration of 5 ng/ml or higher were considered not abstinent; Spindle et al., 2017) . Ultimately, 18 of the 33 ECIG-experienced and 21 of the 31 ECIG-naïve individuals met this criterion and were considered to have abstained from nicotine before each of the four sessions.
Before conducting the analyses previously described, data were analyzed to understand whether abstinence status influenced each outcome measure within each group. For each group (ECIG experienced and ECIG naïve), mixed ANOVAs with abstinence status as the between-subject factor (abstinent or nonabstinent) and condition (4 levels) and time (10 levels for plasma, 10 for HR, 2 for topography, 10 for subjective variables except two questionnaires with 9 time points) as the within-subject factors were conducted to test for abstinence effects. In the results, this analysis by abstinence status preceded and informed the overall analysis.
Results

Participant Characteristics
Data from 33 ECIG-experienced individuals and 31 ECIG-naïve cigarette smokers were included in the final study analyses. Neither participant age nor race differed significantly across groups (see Table 1 ). Collapsed across group, mean (SD) age was 30.6 (9.1) years. Forty participants were Caucasian, 15 were Black/ African American, 2 were Hispanic/Latino, 1 was Hawaiian/other Pacific Islander, 1 reported more than one race, and 5 reported "other." As anticipated, groups differed on several demographic characteristics pertaining to eligibility criteria. For example, ECIG-experienced individuals smoked significantly fewer cigarettes/day (M ϭ 0.2; SD ϭ 0.8) relative to ECIG-naïve cigarette smokers (M ϭ 16.5; SD ϭ 9.4). Although eligibility criteria allowed for some daily cigarette use (Յ5 cigarettes per day), 29 of 33 ECIG-experienced participants reported no current cigarette use. In addition, ECIG-experienced individuals had significantly lower expired air CO at screening (M ϭ 3.0 ppm; SD ϭ 2.1; consistent with CO of nonsmokers; Perkins, Karelitz, & Jao, 2013; Cropsey, Eldridge, Weaver, Villalobos, & Stitzer, 2006) relative to ECIG-naïve individuals (M ϭ 19.9 ppm; SD ϭ 5.6). Furthermore, ECIG-naïve cigarette smokers had significantly less experience with ECIGs, and mean (SD) lifetime ECIG use reported was 2 (1.6) uses. In addition, groups differed on some demographic characteristics that did not pertain to the differing eligibility criteria. For example, significantly fewer ECIG-experienced women completed the study (n ϭ 6) relative to ECIG-naïve individuals (n ϭ 13), and ECIG-experienced individuals had significantly lower scores on the Penn State Dependence Questionnaire at screening (M ϭ 9.9; SD ϭ 3.4; Foulds et al., 2015) relative to ECIG-naïve individuals (M ϭ 12.2; SD ϭ 4.0; all ps Ͻ .05). As Table 1 shows, ECIG-experienced individuals reported that they had been using ECIGs for almost 1.5 years, used a liquid nicotine concentration of approximately 18 mg/ml on average, and consumed approximately 3.3 ml of ECIG liquid each day. This document is copyrighted by the American Psychological Association or one of its allied publishers.
Plasma Nicotine
Plasma nicotine data were first used to evaluate potential effects of abstinence status for ECIG-experienced and -naïve individuals. A significant main effect of abstinence status was observed for ECIG-experienced (F(1, 31) ϭ 9.8 p Ͻ .05, p 2 ϭ .24) and ECIG-naïve individuals (F(1, 29) ϭ 9.6, p Ͻ .05, p 2 ϭ .25). Given that the criterion for determining abstinence status was baseline plasma nicotine concentration, inspection of the data revealed that for both groups, baseline plasma nicotine concentration was higher in some conditions for nonabstinent participants. For example, for ECIG-experienced participants in the 36-mg/ml condition, nonabstinent participants had a mean baseline plasma nicotine concentration of 7.1 ng/ml (SD ϭ 5.2) whereas abstinent participants had a mean baseline concentration of 2.0 ng/ml (SD ϭ 0.5; ns, Tukey's HSD). Likewise, for ECIG-naïve smokers in the 36-mg/ml condition, nonabstinent participants had a mean baseline plasma nicotine concentration of 5.8 ng/ml (SD ϭ 4.9) whereas abstinent participants had a mean baseline concentration of 2.4 ng/ml (SD ϭ 0.8; ns, Tukey's HSD). To control for these baseline differences in plasma nicotine concentration, the same analyses (i.e., mixed ANOVAs with abstinence status as the between-subject factor) were conducted using plasma nicotine concentration change scores, referred to as "nicotine boost" and calculated by subtracting baseline plasma nicotine from post ECIG-use plasma nicotine values. These analyses revealed no significant interactions or main effects involving abstinence status for either group, suggesting that the observed effects of abstinence status using the raw data were a result of baseline differences. Thus, the final analyses were conducted using nicotine boost data and included all participants. Table 2 shows the statistical analysis results for nicotine boost. There was a significant three-way condition by time by group interaction (F(27, 1,674) ϭ 2.6, p Ͻ .01, p 2 ϭ .04) in addition to several other significant interactions and main effects (see Table  2 ). Figure 1 shows mean nicotine boost, over time, by condition for ECIG-experienced and -naïve individuals. For ECIG-experienced individuals, immediately after bout 1, mean (SD) nicotine boost increased significantly from baseline in all active liquid nicotine concentrations such that for 8 mg/ml the plasma nicotine concentration was 8.2 ng/ml (7.8), for 18 mg/ml it was 13.0 ng/ml (6.2), and for 36 mg/ml it was 17.9 ng/ml (17.2; ps Ͻ .05, Tukey's HSD). For ECIG-naïve cigarette smokers, immediately after bout 1, mean (SD) plasma nicotine boost increased significantly from baseline when using the 18-and 36-mg/ml conditions such that for 18 mg/ml it was 6.2 ng/ml (10.2) and for 36 mg/ml it was 6.8 ng/ml (7.1; ps Ͻ .05, Tukey's HSD). Similar patterns in nicotine boost were observed for both groups immediately after bout 2.
Planned contrasts, conducted for the time points immediately after bout 1 and 2, revealed significant between-group differences (ECIG-experienced vs. -naïve) after bout 1 in the 8-, 18-, and 36-mg/ml conditions (ts (62) Ͻ Ϫ0.17; ps Ͻ .05) but not in the 0-mg/ml condition. Overall, ECIG-experienced individuals obtained significantly higher plasma nicotine boost on average, immediately after bout 1 in all active nicotine conditions, and immediately after bout 2 in the 36-mg/ml condition (see Figure 1) .
HR
Potential effects of abstinence status on HR values were evaluated for ECIG-experienced and -naïve individuals. A significant three-way condition by time by abstinence status interaction was observed for ECIG-experienced individuals (F(27, 837) ϭ 1.9, p Ͻ .05, p 2 ϭ .06), but no significant interactions or main effects of abstinence status were observed for ECIG-naïve individuals. To explore whether significant differences by abstinence status occurred due to baseline differences in HR (as seen previously with plasma nicotine concentration), mixed ANOVAs with abstinence status as the between-subject factor were conducted using HR difference scores, and the same three-way interaction involving abstinence status remained significant (F(27, 837) ϭ 1.9, p Ͻ .05, p 2 ϭ .06). Because abstinence status appeared to influence HR in ECIG-experienced participants, despite using difference scores to correct for baseline differences, final analyses were conducted (Heatherton et al., 1991) was modified such that the word e-cigarette appeared for ECIG-experienced individuals.
d Penn State Dependence Index (Foulds et al., 2015) ; Electronic Cigarette Dependence Index was administered to ECIG-experienced individuals and the Cigarette Dependence Index was administered to ECIG-naïve cigarette smokers. This document is copyrighted by the American Psychological Association or one of its allied publishers.
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using raw HR data and only abstinent participants for both groups (ECIG experienced, N ϭ 18; ECIG naïve, N ϭ 21).
As Table 2 shows, significant condition by time (F(27, 999) ϭ 10.0, p Ͻ .01, p 2 ϭ .21) and significant time by group (F(9, 333) ϭ 3.3, p Ͻ .008, p 2 ϭ .08) interactions were observed for HR, in addition to several significant main effects. Planned contrasts revealed no significant between-group differences in HR at baseline or immediately after bout 1 or 2 (ts (37) Ͼ Ϫ2.1, ns). For both groups, HR increased significantly from baseline immediately after bout 1 and 2 in all active liquid nicotine concentrations (8, 18, and 36 mg/ml) but not the 0-mg/ml condition. Thus, in the 0-mg/ml condition collapsed across group, mean (SD) HR increased (nonsignificantly) from 69.6 bpm (8.7) before bout 1 to 72.2 bpm (7.5) postbout 1 and from 65.9 bpm (8.4) before bout 2 to 68.1 bpm (7.5) postbout 2. However, in the 8-mg/ml condition, collapsed across group, mean (SD) HR increased from 66.4 bpm (6.5) before bout 1 to 73.0 bpm (7.4) postbout 1 and from 65.1 bpm (6.5) before bout 2 to 69.9 bpm (7.8) postbout 2 (both increases significant; ps Ͻ .05, Tukey's HSD). In the 18-mg/ml condition, collapsed across group mean (SD) HR increased from 66.4 bpm (7.6) before bout 1 to 75.8 bpm (7.9) postbout 1 and from 65.7 bpm (7.7) before bout 2 to 71.6 bpm (8.2) postbout 2 (both increases significant; ps Ͻ .05, Tukey's HSD). In the 36-mg/ml condition, collapsed across group mean (SD) HR increased from 66.6 bpm (7.1) before bout 1 to 77.0 bpm (8.6) postbout 1 and from 67.3 bpm (7.8) before bout 2 to 72.7 bpm (9.3) postbout 2 (both increases significant; ps Ͻ .05, Tukey's HSD).
Puff Topography
Raw data for puff topography variables of interest (i.e., puff duration, volume, and flow rate) were used to evaluate potential effects of abstinence status (because puff number was controlled at 10 puffs/bout and IPI was controlled at 30 sec, these variables are not analyzed as outcome measures). No significant interactions or main effects involving abstinence status were observed for any topography variables for either group; thus, data from all participants were included in the analysis.
Mean (SD) puffing parameters for ECIG-experienced and -naïve individuals are displayed in Table 3 . For puff duration, a significant time by group interaction was observed (F(3, 186) ϭ 5.42, p Ͻ .05, p 2 ϭ .08) in addition to significant main effects of condition (F(3, 186) ϭ 9.67, p Ͻ .01, p 2 ϭ .14), time (F(1, 62) ϭ 19.56, p Ͻ .001, p 2 ϭ .24), and group (F(1, 62) ϭ 28.28, p Ͻ .001, p 2 ϭ .31). Planned contrasts revealed significant between-group differences indicating that ECIG-experienced individuals took significantly longer puffs relative to ECIG-naïve individuals in all conditions and during each ECIG-use bout (ts (62) Ͼ 3.3, ps Ͻ .05).
For puff volume, a significant condition by time interaction was observed (F(3, 186) ϭ 4.9, p Ͻ .01, p 2 ϭ .07) in addition to significant main effects of condition (F(3, 186) ϭ 7.78, p Ͻ .001, p 2 ϭ .11), time (F(1, 62) ϭ 23.0, p Ͻ .001, p 2 ϭ 0.27), and group (F(1, 62) ϭ 8.7, p Ͻ .05, p 2 ϭ .12). Planned contrasts revealed significant between-group differences indicating that ECIGexperienced individuals took significantly larger puffs relative to ECIG-naïve individuals during bout 1 in the 0-, 8-, and 18-mg/ml conditions and during bout 2 in the 0-and 8-mg/ml conditions (ts (62) Ͼ 3.1, ps Ͻ .05).
For flow rate, a significant time by group interaction was observed (F(1, 62) ϭ 4.4, p Ͻ .05, p 2 ϭ .07) in addition to a significant main effect of time (F(1, 62) ϭ 7.56, p Ͻ .01, p 2 ϭ .11). Planned contrasts revealed significant between-group differences in the 18-mg/ml condition only during bout 2 (t(62) ϭ Ϫ2.4, p Ͻ .03).
Subjective Measures
Raw data for each subjective questionnaire were used to evaluate potential effects of abstinence status for ECIG-experienced and -naïve individuals. No significant interactions or main effects involving abstinence status were observed for any subjective measures for either group; thus, data from all participants were included in the analysis (see Table 2 ).
Hughes-Hatsukami Withdrawal Scale. Significant condition by group interactions were observed for the items "Craving," , asterisks indicate significant differences from the 0-mg/ml condition at that time point, and pound symbols indicate significant differences between the 8-and 36-mg/ml condition at that time point (ps Ͻ .05; Tukey's HSD). Plus signs indicate significant between-group differences at that time point for that concentration (only conducted on time points immediately postbout; independent t tests; ps Ͻ .05).
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"Depression," "Drowsy," and "Urge" (Fs (3, 186) Ն 3.6, ps Ͻ .05, p 2 s Յ .07); significant condition by time interactions were also observed for the items "Craving" and "Urge" (Fs (3, 186) Ն 4.4, ps Ͻ .01, p 2 s Յ .07). Overall, for these items, the magnitude of the decrease in scores was dependent on condition and group such that the decrease in scores was more pronounced when using higher liquid nicotine concentrations and among ECIG-experienced individuals. For ECIG-experienced individuals, mean scores for "Urge" decreased significantly relative to baseline immediately after bout 1 and 2 in the 8-, 18-, and 36-mg/ml conditions and for ECIG-naïve individuals scores decreased significantly relative to baseline immediately after bout 1 and 2 in the 18-and 36-mg/ml conditions ( Figure 2, A and B) . For example, in the 36-mg/ml condition, mean (SD) scores decreased from 62.3 (33.4) before bout 1 to 26.6 (25.8) immediately after bout 1 for ECIGexperienced individuals and the scores decreased from 71.9 (32.3) immediately before bout 1 to 40.5 (36.4) immediately after bout 1 for ECIG-naïve individuals (ps Ͻ .05, Tukey's HSD). A similar pattern was observed for "Craving." In addition, for the item "Depression," planned contrasts revealed significant betweengroup differences such that ECIG-naïve smokers had significantly higher scores relative to ECIG-experienced individuals at baseline and immediately after bout 1 and 2 in the 0-and 8-mg/ml conditions (ts (62) Ͼ Ϫ2.7, ps Ͻ .05). For example, immediately after bout 1 in the 8-mg/ml condition, mean (SD) scores for "Depression" were 1.6 (3.5) for ECIG-experienced but 8.7 (15.1) for ECIG-naïve individuals. A similar pattern was observed for the item "Drowsy."
In addition to significant interactions, significant main effects of condition, time, and group were observed and are presented in Table 2 . One item, "Impatient," revealed significant main effects for condition, time, and group and is presented in Figure 2 (C and D). Post hoc tests revealed no statistically significant differences across time points or conditions for either group. Planned contrasts revealed significant between-group differences such that ECIGnaïve smokers had significantly higher scores for "Impatient" immediately after bout 1 in the 0-, 18-, and 36-mg/ml conditions and immediately after bout 2 in all conditions relative to ECIGexperienced individuals (ts (62) Ͼ Ϫ2.6, ps Ͻ .05). For example, in the 36-mg/ml condition, mean (SD) scores for ECIGexperienced individuals were 7.6 (14.0) immediately after bout 1 and 11.6 (21.2) immediately after bout 2 whereas for ECIG-naïve individuals scores were 20.8 (25.7) immediately after bout 1 and 27.0 (32.9) immediately after bout 2 (ps Ͻ .05). A similar pattern was observed for the item "Irritable."
Tiffany-Drobes QSU-Brief. Significant condition by time interactions were observed for both QSU factors (Fs (27, 1,647) Ն 1.7, ps Ͻ .05, p 2 s Յ .09) and a condition by group interaction was observed for QSU Factor 1 (F(3, 186) ϭ 3.7, p Ͻ .05, p 2 ϭ .06), with each factor showing decreases immediately after bout 1 and 2 and with the magnitude of these decreases being more apparent when using higher liquid nicotine concentrations and among ECIG-experienced individuals. For example, Figure 2 (E and F) displays data from QSU Factor 1, for which scores decreased significantly after bout 1, relative to baseline, for both groups in the 18-and 36-mg/ml conditions and in some instances in the 8-mg/ml condition. For example, in the 36-mg/ml condition, mean (SD) scores decreased significantly from 22.4 (7.4) before bout 1 to 11.8 (8.6) immediately after bout 1 for ECIG-experienced individuals and scores decreased significantly from 23.0 (8.0) immediately before bout 1 to 15.2 (10.2) immediately after bout 1 for ECIG-naïve individuals (ps Ͻ .05, Tukey's HSD). A similar pattern was observed for bout 2.
Direct effects of nicotine. A significant condition by group interaction was observed for the item "Sweaty" (F(3, 186) ϭ 3.7, p Ͻ .02, p 2 ϭ .06). Planned contrasts revealed significant between-group differences for "Sweaty" immediately after bout 1 and 2 only in the 8-mg/ml condition (ts (62) Ͼ Ϫ2.6, ps Ͻ .05). For example, immediately after bout 1 in the 8-mg/ml condition, mean (SD) scores for "Sweaty" were 1.5 (3.7) for ECIGexperienced and 9.0 (17.9) for ECIG-naïve individuals. In addition, significant main effects of group were observed for "Nausea," "Nervous," "Salivate," and "Sweaty" (Fs (1, 62) Ն 4.3, ps Ͻ .05, p 2 s Յ .12), with ECIG-naïve individuals reporting overall higher scores for these items.
Direct effects of ECIG use. Significant condition by group interactions were observed for "Awake," "Pleasant," and "Satisfy" (Fs (3, 186) Ն 3.0, ps Ͻ .05, p 2 s Յ .09). Figure 2 (G and H) displays data for the item "Satisfy," and overall patterns revealed that immediately after bout 1, significant differences between the a Significant differences from the 0-mg/ml condition for that bout. b Across-bout differences for that condition and group. c Significant differences between ECIG-experienced and -naïve individuals. In addition, puff number (10) and IPI (30 sec) were experimentally controlled (see Method). This document is copyrighted by the American Psychological Association or one of its allied publishers.
0-mg/ml condition and the 8-, 18-, and 36-mg/ml conditions were observed for ECIG-experienced individuals but not ECIG-naïve individuals (ps Ͻ .05, Tukey's HSD). For example, immediately after bout 1, scores for "Satisfy" for ECIG-experienced individuals were 33.4 (33.1) for the 0-mg/ml condition, 50.8 (33.0) for 8 mg/ml, 61.0 (30.5) for 18 mg/ml, and 60.0 (30.1) for 36 mg/ml (ps Ͻ .05, Tukey's HSD). Conversely, immediately after bout 1, scores for "Satisfy" for ECIG-naïve individuals were 41.5 (33.9) for the 0-mg/ml condition, 42.7 (30.1) for 8 mg/ml, 50.7 (34.2) for 18 mg/ml, and 45.1 (35.1) for 36 mg/ml. Planned contrasts revealed no significant between-group differences for "Satisfy."
For the item "Right Now," significant condition by time (F(24, 1,488) ϭ 4.2, p Ͻ .01, p 2 ϭ .06) and time by group (F(8, 496) ϭ 2.5, p Ͻ .05, p 2 ϭ .04) interactions were observed. Planned contrasts revealed significant between-group differences, with ECIG-experienced individuals reporting significantly higher scores relative to ECIG-naïve individuals in the 0-and 8-mg/ml conditions immediately after bout 1 but not after bout 2 (ts (62) Ͼ 2.2, ps Ͻ .05). For example, immediately after bout 1 in the 8-mg/ml condition, ECIG-experienced individuals' mean (SD) score was 74.0 (32.2) and for ECIG-naïve individuals the score was 47.0 (39.5). Finally, significant main effects of condition were This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
observed for all 10 items (Fs (3, 186) Ն 3.6, ps Ͻ .05, p 2 s Յ .14); however, further post hoc testing revealed no significant differences across conditions. Topography Acceptability Questionnaire. No significant interactions for any item were observed; however, significant main effects of time were observed for "Altered e-cigarette use behavior" and "Increased awareness" (Fs (8, 496 ) Ն 3.6, ps Ͻ .05, p 2 s Յ .06). Post hoc tests revealed no statistically significant differences across time points for either group. A significant main effect of group was observed for the item "Made vaping less likely" (F(1, 62) ϭ 5.7, p Ͻ .05, p 2 ϭ .08), with ECIG-naïve cigarette smokers reporting overall higher scores relative to ECIG-experienced individuals.
Discussion
This study was the first to systematically evaluate the extent to which liquid nicotine concentration and user experience influence plasma nicotine concentration, HR, puff topography, and subjective effects after acute ECIG use. Results from this study indicate that ECIG-associated nicotine delivery depends on liquid nicotine concentration and user experience, ECIG-delivered nicotine is physiologically active as indexed by HR increases, user puff topography differs as a function of user experience and liquid nicotine concentration, ECIG-use suppresses nicotine/tobacco abstinence symptoms in experienced ECIG users and ECIG-naïve cigarette smokers, and the magnitude of abstinence symptom suppression depends on liquid nicotine concentration, at least on some measures. Taken together, results from this study are relevant to efforts intended to regulate and/or predict ECIG effects.
The present study demonstrated that ECIG-associated nicotine delivery is related directly to liquid nicotine concentration (when device power and other liquid constituents are held constant), can meet or exceed the nicotine delivery of a tobacco cigarette, and depends on user experience. The direct relationship between liquid nicotine concentration and user plasma nicotine concentration is illustrated in Figure 1 and can be demonstrated more clearly when the mean nicotine boost data are collapsed across group: immediately after bout 1, mean (SD) nicotine boost was Ϫ0.1 ng/ml (1.5) in the 0-mg/ml condition, 6.0 ng/ml (6.6) in the 8-mg/ml condition, 10.0 ng/ml (12.2) in the 18-mg/ml condition, and 13.0 ng/ml (14.3) in the 36-mg/ml condition. Some participants in this study exceeded the nicotine boost typically observed after smoking a single tobacco cigarette (i.e., ϳ15-20 ng/ml; Patterson et al., 2003; Vansickel et al., 2010; Yan & D'Ruiz, 2015) . For example, although mean plasma nicotine boost observed among experienced ECIG users immediately after bout 1 in the 36-mg/ml condition was 17.9 ng/ml, nine participants achieved a plasma nicotine boost twice as high (i.e., Ն36 ng/ml), suggesting that some experienced ECIG users can obtain nicotine from an ECIG with great efficiency. These nicotine delivery results are consistent with other studies that indicate that ECIGs can meet or exceed the nicotine delivery profile of combustible tobacco cigarettes (Dawkins et al., 2016; Spindle et al., 2017; Wagener et al., 2017) . The plasma nicotine increases observed in the 8-, 18-, and 36-mg/ml conditions were physiologically active, as indicated by accompanying significant increases in HR in those conditions, but not in the 0-mg/ml nicotine condition (in which plasma nicotine did not significantly increase). In addition, similar to a previous report (Farsalinos et al., 2015) , the present study demonstrated that nicotine delivery differed across ECIG-experienced and -naïve individuals despite controlling for several characteristics that may influence nicotine delivery (e.g., device power, liquid PG:VG ratio, puff number), and these differences may be explained by differences in user puff topography.
Puff topography results were dependent on user experience and liquid nicotine concentration. The between-group puff topography results suggest a relationship between longer/larger puffs and higher plasma nicotine concentration (Farsalinos et al., 2015 ; see also Talih et al., 2015) . In this study, ECIG-experienced individuals took significantly longer and larger puffs relative to ECIGnaïve smokers in every condition (see Table 3 ). For example, collapsed across condition and time (bout), mean (SD) puff duration was 5.6 sec (3.0) for ECIG-experienced individuals and 2.9 sec (1.5) for ECIG-naïve smokers, and mean (SD) puff volume was 161.5 ml/sec (152.1) for ECIG-experienced individuals and 94.9 ml/sec (68.7) for ECIG-naïve individuals. The possibility of a relationship between longer puffs and higher plasma nicotine concentration is strengthened by the observation of significant positive correlations for puff duration and postbout plasma nicotine concentration for the 8-(r ϭ .53), 18-(r ϭ .56), and 36-mg/ml conditions (r ϭ .44, all ps Ͻ .01) and no such significant correlation for any other puff topography outcome. Puff topography was also related to liquid nicotine concentration. For example, during bout 1, collapsed across group, mean (SD) puff duration was 4.7 sec (2.4) in the 0-mg/ml condition, 4.4 sec (4.0) in the 8-mg/ml condition, 4.0 sec (3.7) in the 18-mg/ml condition, and 3.5 sec (2.8) in the 36-mg/ml condition. For puff volume, during bout 1, collapsed across group, mean (SD) puff volume was 140.1 ml/sec (121.8) in the 0-mg/ml condition, 142.5 ml/sec (116.7) in the 8-mg/ml condition, 107.4 ml/sec (73.5) in the 18-mg/ml condition, and 96.7 ml/sec (130.7) in the 36-mg/ml condition. These longer/ larger puffs when using lower liquid nicotine concentrations may be analogous to self-titration observed among cigarette smokers (Ashton, Stepney, & Thompson, 1979) . Indeed, compensatory puffing behavior was observed in a recent study in which experienced ECIG users increased their puff number and duration as well as volume of liquid consumed when using a 6-mg/ml liquid nicotine concentration relative to a 24-mg/ml concentration under ad libitum puffing conditions (Dawkins et al., 2016) . However, in the present study, without an "own-brand" control condition (e.g., own-brand ECIG or cigarette control) or an ad libitum puffing period, the extent to which the observed differences in puff duration/volume reflect compensatory behavior (either to get more nicotine from lower concentration liquids or less nicotine from higher concentration liquids) is unclear.
ECIG-use suppressed nicotine/tobacco abstinence symptoms in ECIG-experienced individuals and ECIG-naïve smokers; for some items, the magnitude of abstinence symptom suppression was dependent on liquid nicotine concentration and user experience. For example, for the Hughes-Hatsukami item "Urge," reductions for both groups were more pronounced as liquid nicotine concentration increased. For example, collapsed across group, mean (SD) scores for "Urge" immediately after bout 1 were 56.0 (33.0) in the 0-mg/ml condition, 46.0 (30.4) in the 8-mg/ml condition, 45.2 (32.0) in the 18-mg/ml condition, and 33.3 (31.9) in the 36-mg/ml condition. A similar pattern was observed for the item "Craving" and QSU-brief Factors 1 and 2, highlighting the importance of This document is copyrighted by the American Psychological Association or one of its allied publishers.
liquid nicotine concentration in abstinence symptom suppression. In cigarette smokers, suppression of tobacco/nicotine abstinence symptoms after nicotine administration is considered one indicator of tobacco/nicotine dependence (e.g., Carter & Griffiths, 2009; Eissenberg, 2004) ; therefore, these results suggest that the ECIGs used by the ECIG-experienced participants in this study were capable of supporting tobacco/nicotine dependence. This conclusion is supported by the observation of similar FTND scores in experienced ECIG users relative to ECIG-naïve cigarette smokers, although scores were lower on the Penn State Dependence Index (see Table 1 ). In addition to suppressing nicotine/tobacco abstinence symptoms, ECIG use also produced other subjective effects, some of which depended upon ECIG experience. For example, experienced ECIG users rated "Satisfy" in the 8-, 18-, and 36-mg/ml conditions significantly higher relative to the 0-mg/ml condition, and as liquid nicotine concentration increased, so did "Satisfy" ratings, indicating a preference for an ECIG containing more rather than less nicotine. Conversely, ECIG-naïve cigarette smokers rated "Satisfy" similarly across liquid nicotine concentrations, including 0 mg/ml, suggesting that unlike experienced ECIG users, ECIGnaïve smokers may have been unable to differentiate across liquid nicotine concentrations or did not consider ECIGs with higher liquid nicotine concentration to be more satisfying. Alternatively, the similar scores across liquid nicotine concentration for ECIGnaïve smokers on this measure may reflect their overall inexperience with these products. Understanding the factors that influence the subjective effects of ECIG-use will be important for understanding their abuse liability in general, and perhaps particularly important if ECIGs are to substitute completely for tobacco cigarettes among cigarette-smoking populations (e.g., Etter, 2013; Hajek, 2014) .
This study had several important limitations. First, the results obtained from this study's directed puffing protocol (10 puffs with 30-sec IPI) may differ from ad libitum puffing. Although there are several advantages to controlling puff topography parameters (e.g., ability to compare across studies and products, reducing confounds associated with participants taking different puff number), future studies may seek to evaluate ECIG nicotine delivery and puff topography in a more naturalistic manner with an ad libitum puffing protocol (e.g., Spindle et al., 2017; Yan & D'Ruiz, 2015) . Second, this study did not include an own-brand control condition (e.g., own-brand ECIG for experienced ECIG users and combustible tobacco cigarette for ECIG-naive cigarette smokers) that would have allowed for more direct comparison of participants' usual topography and nicotine delivery. However, several evaluations of nicotine delivery and puff topography when using ownbrand ECIG or tobacco cigarette have been conducted to allow for cross-study comparisons (Spindle et al., 2017; Vansickel et al., 2010; Yan & D'Ruiz, 2015) . Third, although the use of a single cartomizer may not be representative of the cartomizers and tanks typically used by experienced ECIG users, standardization of the cartomizer was necessary to accommodate the topography mouthpiece used and ensures accurate measurement of puff topography; there is an increasing need for topography measurement tools that can be used with advanced-generation ECIGs. Fourth, some participants likely did not comply with the protocol-mandated Ն12 h nicotine/tobacco abstinence before the onset of the study session, highlighting the challenge of studying noncombustible tobacco products for which short-term abstinence cannot be verified immediately before the start of the study session (Blank et al., 2016) . Future clinical laboratory research addressing the acute effects of ECIGs and other noncombustible tobacco products will continue to meet such challenges until a reliable and cost-effective method for verifying abstinence from noncombustible tobacco products is discovered. Fifth, some "ECIG-naïve" cigarette smokers had previously tried ECIGs, and the extent to which these participants' previous encounters with ECIGs may have influenced the results of the present study is unclear. However, most cigarette smokers in the present study reported little to no experience with ECIGs (M ϭ 2 uses; SD ϭ 1.6) before study enrollment.
The findings from the present study have important regulatory implications. The U.S. Food and Drug Administration has begun a process of regulating ECIGs and their "parts and components" (81 FR 28973, 2016) . Effective regulation of ECIGs will require systematic evaluation of these products and the effects they produce, including their ability to deliver nicotine to the user. In this study, some ECIG-experienced individuals received more nicotine from 10 ECIG puffs in the 36-mg/ml condition than has been reported for 10 puffs from a tobacco cigarette (e.g., Vansickel et al., 2010; Yan & D'Ruiz, 2015) . The rationale for ECIG device/ liquid combinations that exceed the nicotine delivery profile of a combustible tobacco cigarette is uncertain, and such products may increase ECIG abuse and dependence (e.g., Cobb, Hendricks, & Eissenberg, 2015) , a particular concern for youth and young adults in the United States and elsewhere (U.S. Department of Health and Human Services, 2016) . For this reason, some jurisdictions have begun to regulate ECIG liquids in an attempt to control ECIG nicotine delivery to the user (e.g., European Union Directive, 2014/40/EU limits ECIG liquid nicotine concentration such that it does not exceed 20 mg/ml). The results presented here highlight liquid nicotine concentration as one factor that influences nicotine delivery and indicate that puff topography is another. Device power is a third potential factor (e.g., Talih et al., 2015) , and recent results indicate that ECIG liquids that are much lower than 20 mg/ml (e.g., ϳ4 mg/ml), when paired with high-powered ECIGs (e.g., 70 W), can meet and in some cases exceed the nicotine delivery profile of a combustible tobacco cigarette (Wagener et al., 2017) .
In light of results from the present study and other results (Wagener et al., 2017) , policies aimed at limiting ECIG nicotine delivery to the user likely will need to account for more factors than liquid nicotine concentration alone-user behavior and device power are also relevant. A mathematical model is available that predicts the rate of ECIG nicotine emissions (e.g., nicotine flux; , and it considers many factors, including liquid nicotine concentration, user behavior, and device power (Talih et al., 2017) . Such models are potentially valuable regulatory tools.
Taken together, the results of this study demonstrate that liquid nicotine concentration is related directly to plasma nicotine concentration and that 10 puffs from a 7.3-W ECIG loaded with 8, 18, or 36 mg/ml liquid nicotine concentration can deliver physiologically active nicotine concentrations to ECIG-experienced and ECIG-naïve individuals. In general, ECIG-experienced individuals obtained significantly more nicotine relative to ECIG-naïve smokers, and this difference can be explained, in part, by differences in puff topography (i.e., longer, larger puffs). In addition, ECIG use This document is copyrighted by the American Psychological Association or one of its allied publishers.
suppresses nicotine/tobacco abstinence symptoms in ECIGexperienced individuals and ECIG-naïve smokers, again depending on liquid nicotine concentration. Findings from the present study are relevant for policymakers seeking to limit ECIG nicotine delivery to the user and for researchers who are evaluating these products as a means for combustible tobacco cigarette replacement.
